Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 70c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.06), $0.70 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $34.84 million versus the consensus estimate of $28.37 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• SanDisk upgraded at JPMorgan after investor day; shares climb